For a study, researchers wanted to examine the prevalence of metabolic syndrome (MetS) in psoriatic arthritis (PsA) patients in a Mediterranean community using the most recent criteria, as well as its relationship with inflammatory biomarkers and serum adipocytokine levels. About 74 patients with PsA and 82 control persons, demographic, clinical, and laboratory data were obtained. The existence of MetS was determined using the current concept of “harmonization.” Adipocytokines in the blood were studied. The test was used to compare continuous variables, and the 2 test was used to compare discrete variables. 

The presence of MetS and blood levels of adipocytokines were compared using multivariate regression models. PsA patients had a greater prevalence of MetS than the control group, with 54.8% vs 36.6% (P=0.02; odds ratio, 2.33; 95% CI; 1.16–4.69). The waist circumference was the most significant variation between the two groups. Mets were shown to have no correlation with articular and skin disease activity or therapy. PsA patients had greater leptin levels and a higher leptin/adiponectin ratio than control subjects: 83.4 vs 51.7 ng/mL (P=0.001) and 6.3×10−3 against 4.1×10−3 (P=0.015), respectively. The levels of adiponectin in the two groups were not significantly different.

The prevalence of MetS was greater in PsA patients compared to non-PsA control persons. Clinicians caring for patients with PsA should be aware of the elevated risk of MetS in PsA patients, which was established in many countries throughout the world. In these individuals, elevated Mets appear to be associated with central obesity, and suitable treatment suggestions are recommended.